Effect of lepirudin on the international normalized ratio

Annals of Pharmacotherapy

Volumn 39, Issue 1, 2005, Pages 28-31

  Stephens, Jennifer L ^d   Koerber, John M ^d,e   Mattson, Joan C ^c,d   Smythe, Maureen A ^a,b,d,e  

^a Health Learning Systems   (United States)

^b GLAXOSMITHKLINE   (United States)

^c SIEMENS CORPORATE RESEARCH   (United States)

^d WILLIAM BEAUMONT HOSPITAL   (United States)

^e WAYNE STATE UNIVERSITY   (United States)

Author keywords

Direct thrombin inhibitor; International normalized ratio; Lepirudin; Thromboplastin

Indexed keywords

ARGATROBAN; LEPIRUDIN; THROMBIN INHIBITOR; WARFARIN;

CORRELATION ANALYSIS; DIAGNOSTIC VALUE; DRUG EFFECT; HUMAN; LINEAR REGRESSION ANALYSIS; MEDICAL ASSESSMENT; MONOTHERAPY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; FEMALE; HIRUDINS; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES;

EID: 11144227722     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E126     Document Type: Review

References (15)

1. Package insert. Refludan (lepirudin). Wayne, NJ: Berlex, October 2002.
2. Package insert. Argatroban. Research Triangle Park, NC: GlaxoSmithKline, November 2003.
3. Sheth SB, DiCicco RA, Hursting MJ, Montague T, Jorkasky DK. Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 2001;85:435-40.
4. Hursting MJ, Zehnder JL, Joffrion JL, Becker JC, Knappenberger GD, Schwarz RP Jr. The international normalized ratio during concurrent warfarin and argatroban anticoagulation: differential contributions of each agent and effects of the choice of thromboplastin used. Clin Chem 1999;45:409-12.
5. Walenga JM, Fasanella AR, Iqbal O, Hoppenstead DA, Ahmad S, Wallis DE, et al. Coagulation laboratory testing in patients with argatroban. Semin Thromb Hemost 1999;25(suppl 1):61-6.
6. Dager WE, White RH. Treatment of heparin-induced thrombocytopenia. Ann Pharmacother 2002;36:489-503. DOI 10.1345/aph.1A204
7. Gosselin RC, Dager WE, King JH, Janatpour K, Mahackian K, Larkin EC, et al. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban on prothrombin time and INR values. Am J Clin Pathol 2004;121:593-9.
8. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
9. Greinacher A, Vopel H, Janssens U, Hach-Wanderle V, Kemkes-Matthes B, Eichler P, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999;99:73-80.
10. Greinacher A, Janssens U, Berg G, Bock M, Kwasny H, Kemkes-Matthes B, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin induced thrombocytopenia. Circulation 1999;100:587-93.
11. Greinacher A, Eichler P, Lubenow N, Kwasny H, Luz M. Heparin-induced thrombocytopenia with thromboembolic complications: metaanalysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range. Blood 2000;96:846-51.
12. Zoldhelyi P, Webster MWI, Fuster V, Grill DE, Gaspar D, Edwards SJ, et al. Thrombosis, platelets and coagulation: recombinant hirudin in patients with chronic, stable coronary artery disease: safety, half-life, and effect on coagulation parameters. Circulation 1993;88:2015-22.
13. Nguyen PH, Baker KR, Rice L. The magnitude of protime INR effect by the direct thrombin inhibitor lepirudin in patients with heparin-induced thrombocytopenia (abstract 4001). Blood 2002;100:130b.
14. Tobu M, Demir M, Iqbal O, Lietz H, Hoppensteadt D, Walenga J, et al. The irrelevance of international normalized ratio in the monitoring of anti-IIa and anti-Xa drugs. Thromb Haemost 2003;1(suppl 1):P1994.
15. Smythe MA, Warkentin TE. Comment: treatment of heparin-induced thrombocytopenia (letter). Ann Pharmacother 2002;36:1483-4. DOI 10.1345/aph.1A204a